Vivos Therapeutics discloses V-Co Investors 4 as beneficial owner in Form 3 filing
VVOS•Form 3 filing shows V-Co Investors 4 as 10% owner
Vivos Therapeutics filed a Form 3 showing V-Co Investors 4 LLC as a 10% owner, triggered by an event dated June 30, 2026.
- V-Co reported direct beneficial ownership of Series A Convertible Preferred Stock convertible into 2,749,330 common shares at an exercise price of $0.46.
- The filing also lists a common stock purchase warrant exercisable June 30, 2026, expiring June 30, 2031, covering 2,749,330 shares at $0.46.
